Furanocoumarins-imperatorin Inhibits Myocardial Hypertrophy Both in Vitro and in Vivo
Overview
Rehabilitation Medicine
Affiliations
The furanocoumarin imperatorin has been reported to have hypotensive effect, and we have investigated its activity on myocardial hypertrophy. Imperatorin displayed similar chromatographic retention peak to verapamil in the model of cardiac muscle/cell membrane chromatography, and could reduce in a concentration-dependent way protein content and cell size of myocytes prestimulated with angiotensin II. The ratio of heart weight to body weight (mg/g) (4.13 ± 0.06 in SHRs, 3.77 ± 0.02 with imperatorin 25 mg kg(-1)d(-1) 16 17 ig, P<0.01) was significantly lower in the imperatorin-treated SHRs. Taken together, our observations show that imperatorin exerts anti-hypertrophic effect both in vitro and in vivo.
Imperatorin's Effect on Myocardial Infarction Based on Network Pharmacology and Molecular Docking.
Zhang R, Wang P, Jin Y, Xie Q, Xiao P Cardiovasc Ther. 2025; 2025():7551459.
PMID: 39834616 PMC: 11745561. DOI: 10.1155/cdr/7551459.
Park J, Shin S, Bu Y, Choi H, Lee K Int J Mol Sci. 2024; 25(8).
PMID: 38673809 PMC: 11050430. DOI: 10.3390/ijms25084223.
The Assessment of the Efficacy of Imperatorin in Reducing Overactive Bladder Symptoms.
Iwaniak P, Dobrowolski P, Wrobel J, Kluz T, Wdowiak A, Bojar I Int J Mol Sci. 2023; 24(21).
PMID: 37958777 PMC: 10648619. DOI: 10.3390/ijms242115793.
The : A Review of Traditional Uses, Phytochemistry and Pharmacology.
Zhao H, Feng Y, Wang M, Wang J, Liu T, Yu J Front Pharmacol. 2022; 13:896637.
PMID: 35847034 PMC: 9283917. DOI: 10.3389/fphar.2022.896637.
Luo D, Zhang J, Li S, Liu W, Yao X, Guo H Front Cell Dev Biol. 2021; 8:592433.
PMID: 33409275 PMC: 7779485. DOI: 10.3389/fcell.2020.592433.